Difference between revisions of "Team:UCL/Achievements"
| (37 intermediate revisions by 4 users not shown) | |||
| Line 62: | Line 62: | ||
#gold {position: relative; float: right; width: 33.333%; margin: 0 auto; background: #F0F0F0; min-height: 100%; display: block; height: auto; padding: 0;} | #gold {position: relative; float: right; width: 33.333%; margin: 0 auto; background: #F0F0F0; min-height: 100%; display: block; height: auto; padding: 0;} | ||
| − | + | #wrapper3 {text-align: center; font-weight: bold;} | |
#gold:hover .medal3 {background-color: #B0975C; transition-property: background-color, color, border-color; | #gold:hover .medal3 {background-color: #B0975C; transition-property: background-color, color, border-color; | ||
| Line 151: | Line 151: | ||
line-height: 1.6; | line-height: 1.6; | ||
letter-spacing: 1.2px; padding-top: 10px;} | letter-spacing: 1.2px; padding-top: 10px;} | ||
| − | #wrapper ol li { list-style-image: none; padding-bottom: 10px; padding-right: | + | #wrapper ol li { list-style-image: none; padding-bottom: 10px; padding-right: 8px; padding-left: 8px;} |
#wrapper ol a, #wrapper ol a:visited {color: #318A8B; font-weight: bold;} | #wrapper ol a, #wrapper ol a:visited {color: #318A8B; font-weight: bold;} | ||
#wrapper ol a:hover {color: #1d8481; -webkit-transition: color ease-in-out 600ms; | #wrapper ol a:hover {color: #1d8481; -webkit-transition: color ease-in-out 600ms; | ||
| Line 160: | Line 160: | ||
#wrapper h2 {font-size: 13px; text-decoration: none; border-bottom: 0px; display: block; background-color: #493C54; color: #fff; font-weight: bold; padding: 14px 0 14px 0; letter-spacing: 4px; text-transform: uppercase; margin: 0px; text-align: center;} | #wrapper h2 {font-size: 13px; text-decoration: none; border-bottom: 0px; display: block; background-color: #493C54; color: #fff; font-weight: bold; padding: 14px 0 14px 0; letter-spacing: 4px; text-transform: uppercase; margin: 0px; text-align: center;} | ||
| − | .achievements {margin: -2px 0 0 0; padding: 5px 0px 0 0; color: #000; font-family: League Script; font-size: 60px; display: block; background: #fff;} | + | .achievements {margin: -2px 0 0 0; padding: 5px 0px 0 0; color: #000; font-family: League Script; font-size: 60px; display: block; background: #fff;padding-bottom:2%;color:grey;} |
| − | @media(max-width:1256px) {} | + | @media(max-width:1256px) {font-size: 14px;} |
| + | |||
| + | @media(max-width:1024px) {#wrapper ol {font-size: 13px;} | ||
| + | |||
| + | .medal1, .medal2, .medal3 {width: 85px; height: 85px; line-height: 85px; border: 6px solid;} | ||
| + | .medalup {height: 30px; width: 25px;} | ||
| − | |||
} | } | ||
| Line 175: | Line 179: | ||
@media(max-width:910px){#wrapper ol {font-size: 13px;} #wrapper {top: 120px;} | @media(max-width:910px){#wrapper ol {font-size: 13px;} #wrapper {top: 120px;} | ||
| − | } | + | |
| + | .medal1, .medal2, .medal3 {width: 70px; height: 70px; line-height: 70px; border: 5px solid;} | ||
| + | .medalup {height: 30px; width: 20px;} | ||
| − | |||
} | } | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| Line 185: | Line 195: | ||
#wrapper2, #bronze, #gold, #silver {width: 100%; position: relative;} | #wrapper2, #bronze, #gold, #silver {width: 100%; position: relative;} | ||
| − | #wrapper {border-radius: 20px; border: 20px solid #fff | + | #wrapper {border-radius: 20px; border: 20px solid #fff;} |
#bronze, #gold, #silver {padding-bottom: 30px;} | #bronze, #gold, #silver {padding-bottom: 30px;} | ||
#wrapper ol {font-size: 15px;} | #wrapper ol {font-size: 15px;} | ||
| − | + | .medal1, .medal2, .medal3 {width: 100px; height: 100px; line-height: 100px; border: 7px solid;} | |
| + | .medalup {height: 30px; width: 30px;} | ||
} | } | ||
| Line 194: | Line 205: | ||
@media(max-width:680px){ | @media(max-width:680px){ | ||
#wrapper ol {font-size: 14px;} | #wrapper ol {font-size: 14px;} | ||
| + | .medal1, .medal2, .medal3 {width: 85px; height: 85px; line-height: 85px; border: 6px solid;} | ||
| + | .medalup {height: 30px; width: 25px;} | ||
| + | |||
} | } | ||
| Line 199: | Line 213: | ||
#wrapper {border-radius: 15px; border: 15px solid #fff;} | #wrapper {border-radius: 15px; border: 15px solid #fff;} | ||
| − | + | .achievements {font-size: 45px;} | |
| − | + | } | |
| + | @media(max-width:420px) { | ||
| + | .medal1, .medal2, .medal3 {width: 70px; height: 70px; line-height: 70px; border: 5px solid;} | ||
| + | .medalup {height: 20px; width: 20px;} | ||
} | } | ||
| + | @media(max-width:380px){ | ||
| + | #wrapper {border-radius: 10px; border: 10px solid #fff;} | ||
| + | .achievements {font-size: 35px;} | ||
| + | #wrapper ol {font-size: 13px;} | ||
| − | + | } | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| Line 223: | Line 238: | ||
<div id="wrapper"> <span class="achievements">Achievements</span> | <div id="wrapper"> <span class="achievements">Achievements</span> | ||
| − | + | <div id="wrapper3"> | |
| + | <br/><br/><br/> | ||
| + | <img src="https://static.igem.org/mediawiki/2015/c/c5/Award-512.png" style="width: 100px;"> <br/><br/> | ||
| + | Best Supporting Entrepreneurship Winner<br/><br/><br/> | ||
| + | Best Composite Part Nomination <br/><br/> | ||
| + | Gold Medal<br/><br/> | ||
| + | Best UK Overgraduate Team<br/><br/><br/> | ||
| + | </div> | ||
<div id="wrapper2"> | <div id="wrapper2"> | ||
| + | |||
| + | |||
| + | |||
<div id="bronze"><h2>bronze</h2> | <div id="bronze"><h2>bronze</h2> | ||
<div class="medalup"></div> <a data-scroll data-options='{ "easing": "linear" }' href="#" class="medal1"></a> | <div class="medalup"></div> <a data-scroll data-options='{ "easing": "linear" }' href="#" class="medal1"></a> | ||
| − | <ol> | + | <ol> |
| − | <li>we have created <a href="https://2015.igem.org/Team:UCL/Parts"> | + | <li>we registered our team</li> |
| + | <li>we completed the judging form</li> | ||
| + | <li>we have created <a href="https://2015.igem.org/Team:UCL/Parts">6 new BioBrick parts</a> and submitted them to the iGEM registry</li> | ||
<li>we have created team wiki to share the story of <a href="https://2015.igem.org/Team:UCL/Description">our project</a> with the world</li> | <li>we have created team wiki to share the story of <a href="https://2015.igem.org/Team:UCL/Description">our project</a> with the world</li> | ||
<li>we have <a href="https://2015.igem.org/Team:UCL/Attributions">attributed</a> our team members, acknowledged our <a href="https://2015.igem.org/Team:UCL/Advisors">advisors</a> and <a href="https://2015.igem.org/Team:UCL/Sponsors">sponsors</a></li> | <li>we have <a href="https://2015.igem.org/Team:UCL/Attributions">attributed</a> our team members, acknowledged our <a href="https://2015.igem.org/Team:UCL/Advisors">advisors</a> and <a href="https://2015.igem.org/Team:UCL/Sponsors">sponsors</a></li> | ||
| Line 246: | Line 273: | ||
<ol> | <ol> | ||
| − | <li>we have experimentally validated <a href="https://2015.igem.org/Team:UCL/ | + | <li>we have experimentally validated <a href="https://2015.igem.org/Team:UCL/Psychobiotics">BBa_K1598002</a> and documented its characterization in the <a href="http://parts.igem.org/Part:BBa_K1598002">iGEM registry</a></li> |
<!--<li> human practice: iGEM projects involve important questions beyond the bench, for example relating to (but not limited to) ethics, sustainability, social justice, safety, security, and intellectual property rights. We refer to these activities as Human Practices in iGEM. Demonstrate how your team has identified, investigated and addressed one or more of these issues in the context of your project.</li> --> | <!--<li> human practice: iGEM projects involve important questions beyond the bench, for example relating to (but not limited to) ethics, sustainability, social justice, safety, security, and intellectual property rights. We refer to these activities as Human Practices in iGEM. Demonstrate how your team has identified, investigated and addressed one or more of these issues in the context of your project.</li> --> | ||
| − | + | <li>we submitted this part to the iGEM Parts registry | |
| + | <li>we identified, investigated and address the ethics, safety and social impact of our project in our <a href="https://2015.igem.org/Team:UCL/Practices">Human Practices</a></li> | ||
</ol> | </ol> | ||
| Line 260: | Line 288: | ||
<ol> | <ol> | ||
| − | <li> | + | <li> We expanded on our silver medal Human Practices activity by investigating the problems associated with traditional antidepressants and anxiolytics, and learning more about their side effects. We then integrated the investigated issues into the design and execution of our project by creating and characterizing the Pregnenolone biobrick, which has been shown to reduce the side effects of numerous drugs.</li> |
| − | + | <li> We carried out various innovative Human Practices activities to reduce mental health stigma using art. We worked with a bioartist, photographer, comic book designer, and mental health charities. We hosted an art exhibition with art from mentally ill people. | |
| − | < | + | <li> We hosted a Synthetic Biology bootcamp at the start of summer and helped the members of a new iGEM team, Birkbeck, get acquainted with all the basic techniques needed to compete in iGEM. It covered software, modelling, assembly, registering parts, etc.We’ve also been a part of a plethora of other Collaborations, as described in our Collaborations page.</li> |
| − | < | + | |
| + | <li>We improved three biobricks in terms of characterisation: <ul><li>pYeaR improved by improved characterisation of sensitivity of promoter</li> | ||
| + | <li>ompR improved by discovering new applcation, NaCl sensitivity</li> | ||
| + | <li>flhDC was not characterised before, we characterised this promoter and confirmed its function</li></ul> | ||
| + | |||
| + | <li> To demonstrate a functional prototype of our project and show this system working under real-world conditions simulated in the lab, we created a microfluidics device, Human Gut-on-a-Chip. We grow our bacteria with mammalian cells in it to study how our probiotic prototype grows and colonizes the gut. We also studied the interactions between the 2 cells, and established that they symbiotically co-exist after over 16hours in real-world conditions.</li> | ||
| + | |||
</ol> | </ol> | ||
Latest revision as of 00:46, 21 November 2015
'
Achievements
Best Supporting Entrepreneurship Winner
Best Composite Part Nomination
Gold Medal
Best UK Overgraduate Team
Best Supporting Entrepreneurship Winner
Best Composite Part Nomination
Gold Medal
Best UK Overgraduate Team
bronze
- we registered our team
- we completed the judging form
- we have created 6 new BioBrick parts and submitted them to the iGEM registry
- we have created team wiki to share the story of our project with the world
- we have attributed our team members, acknowledged our advisors and sponsors
- we are heading to the Giant Jamboree to present a poster and give a presentation
silver
- we have experimentally validated BBa_K1598002 and documented its characterization in the iGEM registry
- we submitted this part to the iGEM Parts registry
- we identified, investigated and address the ethics, safety and social impact of our project in our Human Practices
gold
- We expanded on our silver medal Human Practices activity by investigating the problems associated with traditional antidepressants and anxiolytics, and learning more about their side effects. We then integrated the investigated issues into the design and execution of our project by creating and characterizing the Pregnenolone biobrick, which has been shown to reduce the side effects of numerous drugs.
- We carried out various innovative Human Practices activities to reduce mental health stigma using art. We worked with a bioartist, photographer, comic book designer, and mental health charities. We hosted an art exhibition with art from mentally ill people.
- We hosted a Synthetic Biology bootcamp at the start of summer and helped the members of a new iGEM team, Birkbeck, get acquainted with all the basic techniques needed to compete in iGEM. It covered software, modelling, assembly, registering parts, etc.We’ve also been a part of a plethora of other Collaborations, as described in our Collaborations page.
- We improved three biobricks in terms of characterisation:
- pYeaR improved by improved characterisation of sensitivity of promoter
- ompR improved by discovering new applcation, NaCl sensitivity
- flhDC was not characterised before, we characterised this promoter and confirmed its function
- To demonstrate a functional prototype of our project and show this system working under real-world conditions simulated in the lab, we created a microfluidics device, Human Gut-on-a-Chip. We grow our bacteria with mammalian cells in it to study how our probiotic prototype grows and colonizes the gut. We also studied the interactions between the 2 cells, and established that they symbiotically co-exist after over 16hours in real-world conditions.